Functional Analysis of Rift Valley Fever Virus NSs Encoding a Partial Truncation

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Head, Jennifer A ^a   Kalveram, Birte ^a   Ikegami, Tetsuro ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MESSENGER RNA; NSS PROTEIN; PROTEIN KINASE R; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; RIFT VALLEY FEVER BUNYAVIRUS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

CELL LINE; HUMANS; INTERFERON-BETA; POINT MUTATION; RIFT VALLEY FEVER VIRUS; RNA, MESSENGER; VIRAL NONSTRUCTURAL PROTEINS; VIRULENCE;

BUNYAVIRIDAE; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS;

EID: 84866613090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045730     Document Type: Article

References (80)

1. Ikegami T, Makino S, (2011) The Pathogenesis of Rift Valley Fever. Viruses 3: 493-519.
2. Peters CJ, Meegan JM (1981) Rift Valley Fever. In Handbook Series of Zoonoses, Section B: Viral Zoonoses, Vol1403-420. Boca Raton, FL, CRC Press.
3. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ, (2009) Rift Valley fever virus. J Am Vet Med Assoc 234: 883-893.
4. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J, (2010) Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41: 61.
5. Swanepoel R, Coetzer JAW, (2004) (2004) Rift Valley fever. In Infectious diseases of livestock with special reference to southern Africa. 2nd ed Coetzer JAW, Thompson GR, Tustin RD, et al., editors. Cape Town,: Oxford University Press. pp. 1037-1070.
6. Daubney R, Hudson JR, (1931) Enzootic hepatitis or Rift Valley fever: An undescribed virus disease of sheep cattle and man from east Africa. JPathBact 34: 545-579.
7. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, et al. (2011) Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 17: 2270-2276.
8. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, et al. (2008) Multiple virus lineages sharing recent common ancestry were associated with a Large Rift Valley fever outbreak among livestock in Kenya during 2006-2007. J Virol 82: 11152-11166.
9. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST, (2007) Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 81: 2805-2816.
10. Carroll SA, Reynes JM, Khristova ML, Andriamandimby SF, Rollin PE, et al. (2011) Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance. J Virol 85: 6162-6167.
11. Miller BR, Godsey MS, Crabtree MB, Savage HM, Al-Mazrao Y, et al. (2002) Isolation and genetic characterization of Rift Valley fever virus from Aedes vexans arabiensis, Kingdom of Saudi Arabia. Emerg Infect Dis 8: 1492-1494.
12. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, et al. (2002) Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 8: 1415-1420.
13. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391-2405.
14. Mandell RB, Flick R (2010) Rift Valley fever virus: An unrecognized emerging threat? Hum Vaccin 6.
15. House JA, Turell MJ, Mebus CA, (1992) Rift Valley fever: present status and risk to the Western Hemisphere. Ann N Y Acad Sci 653: 233-242.
16. USDA A, (2005) Part II. 7 CFR Part 331 and 9 CFR Part 121 Agricultural Bioterrorism Protection Act of 2002; Possesion, use, and transfer of biological agents and toxins; final rule. Fed Register 2005 70: 13241-13292.
17. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, et al. (2009) Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5: e1000287.
18. Ikegami T, Won S, Peters CJ, Makino S, (2006) Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 80: 2933-2940.
19. Kalveram B, Lihoradova O, Ikegami T, (2011) NSs Protein of Rift Valley Fever Virus Promotes Post-Translational Downregulation of the TFIIH Subunit p62. J Virol 85: 6234-6243.
20. Schmaljohn C, Nichol ST (2007) Bunyaviridae Knipe,DM, Howley,PM, Griffin,DE, Lamb,RA, Martin,MA, Roizman,B, Straus,SE eds In Fields Virology, 5th ed Lippincott, Williams & Wilkins Philadelphia, PA: 1741-1789.
21. Gerrard SR, Nichol ST, (2007) Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357: 124-133.
22. Giorgi C, Accardi L, Nicoletti L, Gro MC, Takehara K, et al. (1991) Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology 180: 738-753.
23. Muller R, Poch O, Delarue M, Bishop DH, Bouloy M (1994) Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol 75 1345-1352.
24. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, et al. (2004) TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116: 541-550.
25. Billecocq A, Spiegel M, Vialat P, Kohl A, Weber F, et al. (2004) NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 78: 9798-9806.
26. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, et al. (2008) A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 4: e13.
27. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, et al. (2009) Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann N Y Acad Sci 1171 (Suppl 1):: E75-85.
28. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, et al. (2009) NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 83: 4365-4375.
29. Caplen H, Peters CJ, Bishop DH, (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66: 2271-2277.
30. Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, et al. (2011) Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, non-teratogenic, and confers protection from viremia, pyrexia, and abortion following lethal challenge in adult and pregnant sheep. J Virol 85: 12901-12909.
31. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, et al. (2010) Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28: 4581-4587.
32. von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A, et al. (2011) Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29: 5771-5777.
33. Ikegami T, Makino S, (2009) Rift valley fever vaccines. Vaccine 27 (Suppl 4):: D69-72.
34. Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, et al. (1991) Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9: 35-41.
35. Morrill JC, Jennings GB, Caplen H, Turell MJ, Johnson AJ, et al. (1987) Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 48: 1042-1047.
36. Morrill JC, Knauert FK, Ksiazek TG, Meegan JM, Peters CJ, (1989) Rift Valley fever infection of rhesus monkeys: implications for rapid diagnosis of human disease. Res Virol 140: 139-146.
37. Morrill JC, Mebus CA, Peters CJ, (1997) Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58: 1110-1114.
38. Morrill JC, Mebus CA, Peters CJ, (1997) Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58: 1104-1109.
39. Morrill JC, Peters CJ, (2011) Mucosal Immunization of Rhesus Macaques With Rift Valley Fever MP-12 Vaccine. J Infect Dis 204: 617-625.
40. Morrill JC, Peters CJ, (2011) Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. J Infect Dis 204: 229-236.
41. Rusnak JM, Gibbs P, Boudreau E, Clizbe DP, Pittman P, (2011) Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 29: 3222-3229.
42. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, et al. (2000) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18: 181-189.
43. de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, et al. (2010) Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28: 2330-2339.
44. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, et al. (2009) Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385: 409-415.
45. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, et al. (2009) A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397: 187-198.
46. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Holbrook MR, et al. (2010) Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. J Virol Methods 169: 259-268.
47. Pichlmair A, Habjan M, Unger H, Weber F, (2010) Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. Vector Borne Zoonotic Dis 10: 701-703.
48. Kortekaas J, Oreshkova N, Cobos-Jimenez V, Vloet RP, Potgieter CA, et al. (2011) Creation of a non-spreading Rift Valley fever virus. J Virol 85: 12622-12630.
49. Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albarino CG, (2012) Single-Dose Immunization with Virus Replicon Particles Confers Rapid Robust Protection against Rift Valley Fever Virus Challenge. J Virol 86: 4204-4212.
50. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, et al. (2010) Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28: 4394-4401.
51. Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, et al. (2010) Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28: 2271-2276.
52. Bhardwaj N, Heise MT, Ross TM, (2010) Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 4: e725.
53. Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, et al. (2009) A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol 16: 1624-1632.
54. Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, et al. (2011) Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A 108: 14926-14931.
55. Soi RK, Rurangirwa FR, McGuire TC, Rwambo PM, DeMartini JC, et al. (2010) Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol 17: 1842-1849.
56. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24: 7181-7189.
57. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, et al. (2009) Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6: 6.
58. Lorenzo G, Martin-Folgar R, Rodriguez F, Brun A, (2008) Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26: 5255-5262.
59. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, et al. (2006) Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24: 4657-4666.
60. Kende M, Alving CR, Rill WL, Swartz GM Jr, Canonico PG, (1985) Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother 27: 903-907.
61. Kende M, Lupton HW, Rill WL, Levy HB, Canonico PG, (1987) Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother 31: 986-990.
62. Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ, (1989) Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev Infect Dis 11 (Suppl 4):: S815-825.
63. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
64. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, et al. (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 107: 3157-3162.
65. Yadani FZ, Kohl A, Prehaud C, Billecocq A, Bouloy M, (1999) The carboxy-terminal acidic domain of Rift Valley Fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein. J Virol 73: 5018-5025.
66. Ikegami T, Won S, Peters CJ, Makino S, (2005) Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment. J Virol 79: 12106-12111.
67. Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, et al. (2008) Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol 82: 4471-4479.
68. Kawada S, Goto T, Haraguchi H, Ono A, Morikawa Y, (2008) Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag. J Virol 82: 4384-4399.
69. Liao M, Kielian M, (2005) Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 171: 111-120.
70. Sanchez AB, de la Torre JC, (2005) Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 79: 7262-7268.
71. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J, (1996) Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 24: 1010-1017.
72. Walker RC Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, et al. (2010) Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J Virol 84: 5201-5211.
73. Weber PC, Kenny JJ, Wigdahl B, (1992) Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0. J Gen Virol 73: 2955-2961.
74. Zamoto-Niikura A, Terasaki K, Ikegami T, Peters CJ, Makino S, (2009) Rift Valley Fever Virus L Protein Forms a Biologically Active Oligomer. J Virol 83: 12779-12789.
75. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, et al. (2001) Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 75: 1371-1377.
76. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, et al. (1995) Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 53: 405-411.
77. Swanepoel R, Blackburn NK, (1977) Demonstration of nuclear immunofluorescence in Rift Valley fever infected cells. J Gen Virol 34: 557-561.
78. Mansuroglu Z, Josse T, Gilleron J, Billecocq A, Leger P, et al. (2009) Non structural NSs protein of Rift Valley Fever Virus interacts with pericentromeric DNA sequences of the host cell inducing chromosome cohesion and segregation defects. J Virol 84: 928-939.
79. Ito N, Takayama-Ito M, Yamada K, Hosokawa J, Sugiyama M, et al. (2003) Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol Immunol 47: 613-617.
80. Kalveram B, Lihoradova O, Indran SV, Ikegami T (2011) Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy. J Vis Exp: e3400.